Zolpidem

• Insomnia
• Sleep Onset Insomnia
• Sleep Maintenance Insomnia
• Short-Term Insomnia Treatment

Zolpidem, sold under brand names including Ambien, Ambien CR, Edluar, Intermezzo, and Zolpimist, is a non-benzodiazepine sedative-hypnotic in the imidazopyridine class used for the short-term treatment of insomnia. Since its US approval in the early 1990s, it has been one of the most widely prescribed sleep medications in adult medicine, prized for rapid sleep onset, predictable duration of action, and lower next-day residual sedation than older benzodiazepines. Despite this favorable profile, zolpidem carries a Schedule IV controlled substance designation, an FDA boxed warning about complex sleep behaviors, and important sex- and dose-specific differences in metabolism that have led to formal recommendations for lower dosing in women. For patients struggling with persistent insomnia, zolpidem is best regarded as a short-term bridge while behavioral therapies for insomnia (CBT-I), sleep hygiene measures, and assessment of underlying contributors are addressed.

Mechanism of Action

Zolpidem binds to the benzodiazepine binding site on the gamma-aminobutyric acid type A (GABA-A) receptor, the principal inhibitory neurotransmitter receptor in the central nervous system. Unlike traditional benzodiazepines such as lorazepam or clonazepam, zolpidem has selective binding affinity for the alpha-1 subunit-containing GABA-A receptor subtypes. The alpha-1 subtype mediates the sedative and hypnotic effects of GABAergic drugs, while alpha-2 and alpha-3 subtypes mediate anxiolysis and muscle relaxation, and alpha-5 mediates aspects of memory.

This subunit selectivity translates into a relatively pure hypnotic effect, with less anxiolysis, less muscle relaxation, and reduced effects on cognition and memory compared with classical benzodiazepines, although these distinctions become less clear at higher doses. Receptor binding enhances chloride conductance through the GABA-A channel when GABA is present, hyperpolarizing post-synaptic neurons and reducing neuronal firing throughout sleep-regulatory regions of the brain. Zolpidem reaches peak plasma concentration in about 1 to 1.5 hours after immediate-release administration and has a half-life of approximately 1.4 to 4.5 hours, with a longer effective duration for the controlled-release formulation. The relatively short half-life is beneficial for avoiding next-day grogginess but contributes to middle-of-the-night awakenings in some patients, which is partly why the controlled-release and middle-of-the-night sublingual formulations were developed. Women clear zolpidem more slowly than men, which underlies the FDA recommendation for lower starting doses in women. Comprehensive sleep medicine guidance is available through the American Academy of Sleep Medicine.

Clinical Use

The American Academy of Sleep Medicine and the American College of Physicians recommend cognitive behavioral therapy for insomnia (CBT-I) as the first-line treatment for chronic insomnia in adults; pharmacologic therapy is added when CBT-I is unavailable, declined, or insufficient. Within pharmacologic options, zolpidem is one of several recommended agents, alongside dual orexin receptor antagonists such as suvorexant and lemborexant, low-dose doxepin, ramelteon, and the off-label use of trazodone. Comparative effectiveness data show that all hypnotics produce similar modest improvements in subjective and objective sleep parameters; selection often depends on whether sleep onset, sleep maintenance, or both are the predominant complaints, and on side effect tolerability.

Zolpidem immediate-release is best for difficulty falling asleep, since its rapid onset and short duration align with the need to initiate sleep. Zolpidem extended-release (Ambien CR) is suited for patients with both sleep-onset and sleep-maintenance difficulties, providing a more sustained drug level through the night. The sublingual formulation Intermezzo is specifically designed for middle-of-the-night awakening with at least 4 hours remaining before planned wake time. Patient selection considerations include the absence of severe respiratory disease, no history of complex sleep behaviors with hypnotics, no untreated sleep apnea (which may worsen with sedating medications), no concurrent CNS depressants particularly opioids or alcohol, and a willingness to engage in non-pharmacologic strategies such as those discussed in sleep hygiene and circadian rhythm optimization. Our psychiatric and primary care teams typically limit zolpidem prescriptions to short courses (4 weeks or less) with reassessment, although select patients use it longer with structured monitoring.

How to Take It

Zolpidem is taken orally only when the patient is ready for sleep and can devote at least 7 to 8 hours to sleep before needing to be active. The current FDA-recommended starting doses are 5 mg immediate-release for women and 5 to 10 mg for men, with maximum 10 mg per night. For Ambien CR, 6.25 mg is the recommended dose for women and 6.25 to 12.5 mg for men, with maximum 12.5 mg per night. The sublingual middle-of-the-night formulation Intermezzo is dosed at 1.75 mg for women and 3.5 mg for men, taken only if at least 4 hours remain before the planned wake time.

Zolpidem should be taken on an empty stomach, since food delays absorption and slows onset of action. Avoid taking with alcohol, opioids, benzodiazepines, sedating antihistamines, or any other CNS depressants because the additive sedation can cause profound respiratory depression. Patients should never drink alcohol the same evening as a planned dose. If a dose is missed, simply skip it; do not take a dose later in the night unless using the formulation specifically designed for middle-of-the-night use, and only with the requisite remaining sleep time. Tablets are swallowed whole except for the sublingual forms, which dissolve under the tongue. Storage is at room temperature, secured from access by children, adolescents, and persons with substance use history. The first night may bring deeper sleep than typical for the patient and possibly some grogginess on awakening; tolerance to side effects develops within several days for most users.

Monitoring and Follow-Up

Zolpidem does not require laboratory monitoring. Clinical follow-up focuses on benefit, side effects, and signs of dependence or behavioral effects. Patients should keep a brief sleep diary noting bedtime, time to fall asleep, awakenings, total sleep time, perceived restfulness, and any next-day grogginess; this informs whether dose, formulation, or non-pharmacologic strategy adjustments are needed. Initial follow-up at 2 to 4 weeks confirms response and screens for adverse effects.

Red flags include any episode of complex sleep behavior such as sleepwalking, sleep-driving, sleep-eating, or other actions performed without conscious awareness or memory; any such event mandates immediate discontinuation. Persistent next-day sedation, motor impairment, or memory difficulties warrant dose reduction or change of agent. Worsening of mood, new depression, or suicidal ideation should prompt reevaluation. Falls in older adults are a particular concern, especially if combined with other psychoactive medications; periodic medication review and consideration of safer alternatives are important. Tolerance and rebound insomnia upon discontinuation can develop, particularly with use beyond several weeks; tapering rather than abrupt cessation is often advised after extended use. Underlying contributors such as untreated sleep apnea (consider home sleep testing), restless legs syndrome, depression, anxiety, chronic headaches, substance use, environmental disruptors, and excessive caffeine should be assessed periodically. Detailed safety information is at medlineplus.gov.

Special Populations

Elderly patients have substantially reduced clearance and increased sensitivity to all hypnotics. Recommended starting doses are 5 mg for immediate-release and 6.25 mg for controlled-release in older adults regardless of sex, with maximum doses kept at these levels. Falls, hip fractures, motor vehicle accidents, and delirium are more frequent in this population; use should be limited to the shortest necessary duration, and benzodiazepine receptor agonists are listed as potentially inappropriate medications for older adults in the AGS Beers Criteria. Hepatic impairment requires dose reduction (5 mg immediate-release or 6.25 mg controlled-release); severe hepatic impairment is a contraindication.

Renal impairment does not require specific adjustment, but caution is reasonable in significant renal disease. Pregnancy: zolpidem crosses the placenta and use late in pregnancy has been associated with neonatal sedation, hypotonia, and respiratory depression; use during pregnancy should be limited to clear indications when alternatives are inadequate. Lactation: zolpidem appears in breast milk in small amounts; if used during lactation, monitor the infant for sedation, poor feeding, and respiratory changes. Pediatric safety has not been established and zolpidem is not approved for children. Patients with sleep apnea who are not on positive airway pressure therapy may experience worsening hypoxemia from zolpidem and should be evaluated; CPAP-adherent patients with controlled apnea may use zolpidem judiciously. Concurrent CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin) increase zolpidem exposure; CYP3A4 inducers (rifampin) decrease it. Concurrent opioid use markedly increases overdose risk and is generally avoided.

When to Contact Your Doctor

Call the office immediately if any complex sleep behavior occurs (sleepwalking, sleep-driving, sleep-eating, or other actions with no memory of the event); zolpidem must be stopped permanently. Persistent next-day grogginess affecting driving or work performance, falls, memory loss, hallucinations, severe vivid dreams, mood changes, or suicidal thoughts warrant prompt evaluation. Worsening insomnia despite consistent dosing or development of tolerance suggests reassessment is needed. Symptoms of allergic reaction including rash, hives, swelling of the face or throat, and difficulty breathing require emergency care. Suspected overdose, especially in combination with alcohol or other depressants, requires immediate emergency care.

If zolpidem has been used regularly for more than a few weeks, do not stop abruptly without discussing taper strategy, since rebound insomnia and rare withdrawal symptoms can occur. New snoring, witnessed apneas, morning headaches, or excessive daytime sleepiness despite adequate sleep duration may suggest underlying sleep apnea and warrant evaluation. For evaluation of insomnia, consideration of CBT-I or pharmacotherapy, and screening for underlying sleep disorders, contact us or schedule a visit. Detailed dosing tables, drug interactions, and frequently asked questions appear on this page below.